This content is from: Corner Office Short Sellers Hurt by Gilead’s Kite Acquisition Kite Pharma has likely been a target for bearish bets because the cancer-fighting technology it uses — CART — is new to the market, says Wedbush biotechnology analyst David Nierengarten. By Alicia McElhaney August 28, 2017
This content is from: Portfolio Gilead Sciences’ Miracle Drug Combination Investors stand to benefit from Gilead’s top-selling hepatitis C and HIV drugs even as the biotech company is trading at a discount. By Vitaliy Katsenelson February 23, 2016
This content is from: Premium Druckenmiller’s Family Office Unloads Two Major Stocks The legendary macro trader established more new positions than it liquidated during the second quarter. By Stephen Taub August 28, 2018
This content is from: Premium The Hottest Sector Has Attracted the Most Short Interest Longs and shorts are having a tug-o-war over red-hot biotechnology stocks. By Stephen Taub September 11, 2017
This content is from: Portfolio The Sector Politicians Love to Hate — and Why We’re Buying It Pharmaceuticals stocks have been in the crosshairs of politicians on both sides of the aisle. But the noise has created buying opportunities. By Vitaliy Katsenelson March 02, 2017
Sponsored Gilead To Buy Pharmasset For $11B Biopharmaceutical company Gilead Sciences will be acquiring clinical-stage pharmaceutical company Pharmasset. November 22, 2011
Sponsored Adapting to Rapid Change and Finding Opportunities in Fixed Income Sponsored by iShares December 04, 2019
